Skip to main content

Table 5 Comparisons of outcomes between edaravone and non-edaravone groups

From: Association between edaravone use and activities of daily living in older patients with atherothrombotic stroke: an observational study using Japanese real-world data

 

Edaravone group (n = 3825)

Non-edaravone group (n = 1751)

P valuea

Length of stay, days

21 [13, 33]

18 [11, 32]

< 0.001

Δ BIb

15 [0, 50]

10 [0, 45]

< 0.001

BI at discharge

85 [25, 100]

75 [20, 100]

0.602

ADL improvement§, n (%)

2,122/3,452 (61.5)

896/1,573 (57.0)

0.002

BI at discharge ≥ 90, n (%)

1,565/3,452 (45.3)

712/1,573 (45.3)

0.962

mRS at discharge 0–2, n (%)

1,692/3,777 (44.8)

7698/1,718 (44.7)

0.948

in-hospital death, n (%)

150 (3.9)

78 (4.5)

0.351

  1. ADL, activities of daily living; BI, Barthel Index; mRS, modified Rankin Scale
  2. Data are expressed as median [interquartile range], or number (%)
  3. aMann–Whitney U test and chi-squared test were used to compare numerical and categorical data, respectively
  4. bBI at discharge – BI at admission
  5. §(BI at discharge – BI at admission) > 0
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us